Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.82 | N/A | +5.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.82 | N/A | +5.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
AbbVie's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 2.86% increase. Investors may view this as a sign of the company's financial health, despite the lack of revenue data and future guidance. The management's cautious optimism suggests they are focused on maintaining performance in the coming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOCKHEED MARTIN CORP
Oct 22, 2013